The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 June 2026•

1 min read

Abivax Surges 25% on Positive Ulcerative Colitis Drug Data

Key Facts

1Abivax's obefazimod showed positive clinical trial results for ulcerative colitis, driving the stock price up 25%.

2BTIG analyst set a price target of $175 for Abivax, implying 82% upside from $96.15.

3Maintenance study showed 37.2% of patients achieved clinical remission at 44 weeks, with malignancy rates in line with background levels.

In a move reflecting positive momentum for the biotech sector, shares of Abivax surged 25% after the company announced positive results for its drug obefazimod in ulcerative colitis. A maintenance study showed 37.2% of patients achieved clinical remission at 44 weeks, with malignancy rates in line with background levels, alleviating prior safety concerns.

According to reports, the stock rose from $96.15 to around $120 following the announcement, giving the company a market cap of $6.3 billion. A BTIG analyst set a $175 price target, implying 82% upside from the pre-announcement close. The data confirmed the drug's efficacy in maintaining clinical remission with an acceptable safety profile.

As of the close on June 30, 2026, the stock trades near $120, with attention now on upcoming regulatory steps and further trial readouts. The $175 price target could act as a catalyst for investors, though trading volumes and any additional clinical disclosures warrant close monitoring.